The Effect of Dermatology and Teledermatology Consultations on Length of Hospital Admission, 30 Day Readmission Rate, and Antibiotic Use in Patients Presenting With Cellulitis vs Pseudocellulitis in an Academic Inpatient Setting
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03034694|
Recruitment Status : Completed
First Posted : January 27, 2017
Last Update Posted : January 18, 2018
|Condition or disease||Intervention/treatment||Phase|
|Cellulitis||Other: teledermatology consult Other: Routine Care||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||45 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Routine Care vs The use of teledermatology|
|Masking:||Double (Participant, Investigator)|
|Official Title:||The Effect of Dermatology and Teledermatology Consultations on Length of Hospital Admission, 30 Day Readmission Rate, and Antibiotic Use in Patients Presenting With Cellulitis vs Pseudocellulitis in an Academic Inpatient Setting|
|Study Start Date :||January 2016|
|Actual Primary Completion Date :||January 2018|
|Actual Study Completion Date :||January 2018|
Placebo Comparator: Routine Care
The first group will be randomized to routine care of receiving or not receiving a dermatology consult in the hospitalized setting based on the clinical decision of the hospitalist. The patients will see the research coordinator who will take images and for a teledermatology assessment, however, these assessments will not be placed in the chart and the treating hospitalist will not know.
Other: Routine Care
The patient will undergo imaging but this report will not be put into the chart.
Experimental: Teledermatology INtervention
The second arm will be patient randomized to teledermatology intervention. These patients will be imaged by the research coordinator, then the assessment will be placed in the chart for the hospitalist to see although final treatment decisions are still made by the hospitalist.
Other: teledermatology consult
- Length of Hospitalization [ Time Frame: 60 Days ]
- Readmission rate [ Time Frame: 30 Days ]
- Frequency/Use of antibiotics [ Time Frame: 30 days ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03034694
|United States, Ohio|
|The Ohio State University Wexner Medical Center|
|Columbus, Ohio, United States, 43210|
|Principal Investigator:||Benjamin H Kaffenberger, MD||OSU Dermatology|